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Impaired Initiation of Contact Hypersensitivity
by FTY720
Daiki Nakashima1, Kenji Kabashima1, Jun-ichi Sakabe1, Kazunari Sugita1, Takashi Kobayashi2,
Ryutaro Yoshiki1 and Yoshiki Tokura1
FTY720 inhibits lymphocyte emigration from lymphoid organs to peripheral blood by binding one of the
sphingosine-1-phosphate (S1P) receptors, S1P1. We investigated the effects of FTY720 in relation to murine
contact hypersensitivity (CHS). CHS was impaired by FTY720 when administered during the sensitization but
not the elicitation phase. Consistently, adoptive transfer of immunized lymph node cells from mice treated with
FTY720 during the sensitization phase was virtually incapable of inducing CHS response in recipients. FTY720
decreased the number of blood CD44-naive T cells markedly and that of CD44þ memory T cells modestly.
Among memory T cells, the CD62L effector memory subset was more resistant to FTY720 than the CD62Lþ
central memory subset. Accordingly, the level of S1P chemotactic response was high in naive T cells, marginal in
effector memory T cells, and very low in central memory T cells. Consistently, the S1P1 mRNA expression level
was much lower in memory T cells than in naive T cells. These findings demonstrate that S1P–S1P1 signaling is
essential for recirculation of naive T cells. FTY720 seems to decrease the incidence of interactions between
antigen-loaded dendritic cells and circulating naive T-cell clones in the lymph nodes, thereby depressing the
sensitization of naive T cells in CHS.
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INTRODUCTION
Sphingosine-1-phosphate (S1P) is recognized as a potent lipid
mediator important for various physiological processes
(Spiegel and Milstien, 2003; Ishii et al., 2004) that binds to
five subtypes of G-protein-coupled receptors, termed S1P1, 2,
3, 4, and 5 (Sanchez and Hla, 2004; Cyster, 2005). In the
immune system, initial studies for evaluating the roles of
S1P were done with a compound, FTY720. Following its
administration in vivo, FTY720 is rapidly phosphorylated
and binds to S1P receptors, thereby diverting S1P signaling
(Brinkmann et al., 2002; Mandala et al., 2002; Sanchez and
Hla, 2004). FTY720 inhibits lymphocyte emigration from
lymphoid organs by binding to S1P1, resulting in lymphope-
nia (Brinkmann et al., 2002; Graler and Goetzl, 2004;
Matloubian et al., 2004).
Several studies in fetal liver chimeras or in tissue-specific
knockout mice showed that T cells lacking S1P1 are unable to
exit the thymus and that most of the S1P1-deficient B and
T cells are inefficient in exiting secondary lymphoid organs,
constituting one of the checkpoints controlling lymphocyte
homeostasis (Allende et al., 2004; Matloubian et al., 2004;
Cyster, 2005). S1P is a metabolite produced by many cell types,
such as platelets, and is abundant in circulation and low in
secondary lymphoid organs. Lymphocytes are thought to egress
in chemotactic response to S1P (Schwab et al., 2005).
Because FTY720-induced lymphopenia substantially im-
pairs immune responses, FTY720 was considered to have
considerable potential as a therapeutic tool (Fujita et al.,
1996; Suzuki et al., 1996; Chiba et al., 1998; Yanagawa
et al., 1998; Kiuchi et al., 2000). Unlike other established
immunomodulators, FTY720 has no inhibitory effect on
cytokine production by lymphocytes (Yanagawa et al.,
1998). The efficacy of FTY720 has been well established in
animal and human transplantation (Brinkmann et al., 2002;
Budde et al., 2002) and is currently exploited in trials to
enhance survival of incompletely major histocompatibility
complex (MHC)-matched organ grafts (Budde et al., 2002). In
the skin immune system, it has been reported that FTY720
prevented the development of atopic dermatitis-like skin
lesions in NC/Nga mice (Kohno et al., 2004) and animal skin
allograft rejection (Yanagawa et al., 1998, 1999; Luo et al.,
1999). However, the precise mechanism of FTY720’s action
in acquired immune response remains unknown.
The skin is exposed to multiple antigens (Ags) throughout
life and develops Ag-specific immune responses. Murine contact
hypersensitivity (CHS) is one of the models for delayed-type
hypersensitivities, consisting of two phases: sensitization and
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elicitation. During the sensitization phase, cutaneous den-
dritic cells (DCs) similar to epidermal Langerhans cells (LCs)
and dermal DCs serve as professional Ag-presenting
cells (Kabashima et al., 2003b; Mathers and Larregina,
2006). Upon migration, cutaneous DCs undergo a process
of maturation, which is represented by the expression of
co-stimulatory molecules and the delivery of major MHC–Ag
complexes to their surfaces. The mature cutaneous DCs then
activate naive T cells in the draining lymph nodes, thereby
inducing their transformation into Ag-specific memory
T cells. In the elicitation phase, when the same Ag is
exposed, circulating Ag-specific memory T cells migrate into
the skin and are reactivated to initiate inflammation by
producing mediators such as IFN-g (Grabbe and Schwarz,
1998; Kabashima and Miyachi, 2004). Therefore, murine
CHS is one of the suitable models for clarifying the role of
FTY720. Here, we found that the sensitization phase, but not
the elicitation phase, is the acting phase of FTY720, which
presumably inhibits recirculation of naive T cells and reduces
the incidence of interaction between Ag-bearing DCs and
Ag-specific naive T-cell clones.
RESULTS
Impairment of CHS by FTY720 when administered during
the sensitization period
We examined the significance of FTY720-mediated regula-
tion of acquired immune responses in vivo. Using CHS as a
model, we investigated whether FTY720 affected the immune
response to an exogenous Ag. C57BL/6 (B6) mice were
sensitized with DNFB as hapten on day 0. Elicitation with
DNFB on the ears 5 days after sensitization induced a marked
swelling response (Figure 1a). Treatment of mice with
FTY720 12 hours before sensitization produced a significant
decrease in ear thickness (Figure 1a). However, the admin-
istration of FTY720 on day 4.5 after sensitization did not
decrease the ear swelling. The treatment of FTY720 both
12 hours before and 4.5 days after sensitization yielded a
comparably reduced intensity of CHS to only the treatment
with FTY720 12 hours before sensitization. Consistently,
histology of the ears 24 hours after challenge showed
pronounced spongiosis and extensive infiltration of lympho-
cytes in the edematous dermis, which were markedly
reduced by the administration of FTY720 12 hours before
sensitization (Figure 1b). To evaluate the effect of FTY720 on
recall responses at later stages, where immune memory
resides with memory T cells within secondary lymphoid
tissues, we administered FTY720 to mice at later time points
after sensitization. The FTY720 treatment at 9.5 and 14.5
days after sensitization slightly impaired the subsequent
elicitation phase without a statistically significant difference
(Figure 1c). These results suggested that FTY720 impaired the
initiation but not the elicitation of CHS.
The above results indicate that the impairment by FTY720
was due to reduced generation of memory T cells during
sensitization. However, this sensitization-based action of
FTY720 might also affect the elicitation phase, as FTY720 is
known to decrease the number of blood lymphocytes
between 3 hours and 3–5 days after administration (Chiba
et al., 1998; Luo et al., 1999), resulting in a numerical
reduction of T cells participating in the elicitation. Moreover,
S1P1 signaling is important for endothelial cell development
(Allende et al., 2003), which might additionally affect the
CHS response.
To further characterize the acting phase of FTY720 and to
exclude its possible effect on non-hematopoietic cells, we
used an adoptive transfer-induced skin inflammation
model. We isolated T cells from regional lymph nodes of
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Figure 1. Effect of FTY720 on CHS response. (a) B6 mice were sensitized
with DNFB on the abdominal skin and challenged with DNFB on the ears
5 days later. FTY720 was administered 12hours before sensitization
(0.5 days (d)), elicitation (þ 4.5 days), or both (0.5d/þ 4.5d), and the
change in ear thickness after challenge was measured. Columns show the
mean±SD from at least four mice per group. Student’s t-test was performed
between the indicated groups and *Po0.05. (b) Histology of the skin 24 hours
after challenge. The ears of mice after sensitization and elicitation with (right
panel) or without (center panel) FTY720 treatment before sensitization are
shown. The ears of mice that were not sensitized are shown as a control
(left panel). Scale bar¼ 100 mm. Data are from three independent
experiments. (c) B6 mice were sensitized with DNFB on the abdominal skin,
and challenged with DNFB on the ears 5, 10, and 14 days later. FTY720 was
administered 12 hours before challenge (þ 4.5d, þ9.5d, and 14.5d).
Columns show the mean±SD from at least four mice per group.
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DNFB-sensitized donors treated with or without FTY720 and
adoptively transferred the cells into B6 naive recipients. The
recipients of sensitized T cells with FTY720 treatment showed
a suppressed CHS response compared with those without
FTY720 treatment (Figure 2a). Conversely, when T cells from
B6 donors 5 days after sensitization were transferred into B6
naive recipients pretreated with or without FTY720, subse-
quent challenge with DNFB elicited comparable changes in
ear swelling in both experimental groups (Figure 2b). These
results indicate that T cells are responsible for the FTY720-
induced impairment of CHS response and that the critical
time point is the sensitization but not the elicitation period.
Unaffected cutaneous DC function by FTY720
In general, the sensitization phase concerned with cutaneous
DCs consists of maturation in the skin, acquisition of Ag,
migration into the regional lymph nodes, and Ag presentation
to naive T cells. Although FTY720 was reported to down-
modulate DC functions in some animal models (Czeloth
et al., 2005), its action on cutaneous DCs in the acquired
immune response remains unclear. Therefore, we performed
an FITC-induced cutaneous DC migration assay. FITC
topically applied to the skin is taken up by cutaneous DCs,
which then migrate to the draining lymph nodes as FITCþ
MHC class IIþ cells (Kabashima et al., 2003b). We injected
FTY720 or the equivalent amount of normal saline into mice,
applied FITC on the abdomen 12hours later, and isolated
axillary and inguinal draining lymph node cells 24 hours after
FITC application. The number of FITCþ CD11cþ or FITCþ
MHC class IIhiþ cutaneous DCs accumulating 24 hours after
FITC application was not substantially altered by FTY720
treatment (Figure 3a–c). The only positive finding that we
obtained from this series of experiments was that the number
of FITCþ CD86þ cutaneous mature DC subsets was slightly
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Figure 2. CHS response induced by adoptive transfer. (a) Attenuated CHS
response in recipients adoptively transferred with FTY720-treated sensitized
T cells. Lymphocytes were isolated and pooled from lymph nodes of
DNFB-sensitized B6 donors with or without FTY720 treatment and adoptively
transferred into B6 naive recipients. The recipient mice were challenged with
DNFB and the change in ear thickness is shown. (b) Intact CHS response in
recipients adoptively transferred with sensitized B6 T cells. Lymphocytes were
isolated and pooled from lymph nodes of DNFB-sensitized B6 donors and
adoptively transferred into B6 naive recipients pretreated with or without
FTY720. The recipient mice were challenged with DNFB and the change in
ear thickness is shown in panels a and b. Columns show the mean±SD from
five mice per group. Student’s t-test was performed between the indicated
groups. *Po0.05. Data are from three independent experiments.
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Figure 3. Influence of FTY720 on migration and maturation of cutaneous
DCs. (a–d) B6 mice were pretreated with or without FTY720, and their
abdominal skin was painted with FITC 12 hours later. The draining lymph
node cells were collected 24 hours after FITC application and analyzed with
flowcytometry (a). The FITCþ CD11cþ cells (b), FITCþ MHC class IIþ cells
(c), FITCþ CD86þ cells (d), and Langerinþ Langerhans cells (e) per mouse
were enumerated (unpaired Student’s t-test; n¼5 per group). As a control,
mice not painted with FITC were prepared (b–d).
www.jidonline.org 2835
D Nakashima et al.
FTY720 and Contact Hypersensitivity Response
decreased by FTY720, but no statistically significant differ-
ence was noted (P¼0.06, n¼5) (Figure 3d). Recently, the
possible functional differences between LCs and dermal DCs
that migrate from skin to draining LNs were highlighted
(Kissenpfennig and Malissen, 2006; Schroder et al., 2006;
Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al., 2007).
We measured the number of Langerinþ LCs in the regional
lymph nodes 24 hours after FITC application. FTY720 did
not affect the number of Langerinþ FITCþ MHC class IIþ
LCs (Figure 3e) nor that of dermal DCs, calculated as follows:
(FITCþ MHC class IIþ total migrated cutaneous DC)–
(Langerinþ FITCþ MHC class IIþ migrated LCs) (data not
shown).
To further evaluate the physiological significance of
FTY720 on DC functions, we performed an in vitro assay
on T-cell proliferation induced by Ag-loaded DCs. DNFB-
sensitized Thy1.2þ T cells were sorted from the draining
lymph nodes 5 days after DNFB application and incubated
with or without CD11cþ DCs prepared from the draining
lymph nodes 1 day after DNFB application with or without
FTY720 treatment. T-cell proliferation was enhanced by the
addition of Ag-loaded sorted DCs, but the extent of
augmentation was comparable irrespective of FTY720 pre-
treatment (Figure 4).
Alteration of naive but not memory T-cell subsets in blood
after FTY720 treatment
The above results suggest that FTY720 could not affect
cutaneous DC migration or their Ag-presenting ability. To
establish the acquired immune response, Ag-loaded DCs
need to interact with Ag-specific naive T-cell clones in the
draining lymph nodes for their activation and maturation. The
notion that FTY720 inhibits naive T-cell circulation raises
the possibility that DCs are unable to meet a sufficient
number of circulating naive T cells in the lymph nodes of
FTY720-treated mice. Although FTY720 is known to inhibit
T-cell egress from the secondary lymph nodes (Chiba et al.,
1998; Sallusto et al., 1999; Yanagawa et al., 1999; Wherry
et al., 2003; Matloubian et al., 2004), the inhibitory level of
each T-cell subset, that is, naive, central memory, or effector
memory T-cell subset, has not been evaluated quantitatively.
Therefore, we examined the extent of decrease in the
individual’s circulating T-cell subsets after treatment with
FTY720. The blood was drawn by intraocular venipuncture
before and 1, 3, and 5 days after FTY720 administration. A
flow cytometric analysis showed that FTY720 decreased the
frequency of CD4þ CD44-naive T-cell subsets more
profoundly than that of CD4þ CD44þ memory T-cell
subsets 1 day after FTY720 treatment (Figure 5a).
+
+
–+
+
++
–
–FTY720:
DCs:
T cells:
0
4
8
12
16
20
[3 H
]th
ym
id
in
e 
in
co
rp
or
a
tio
n 
(d.
p.m
.×
10
3 )
Figure 4. Effect of FTY720 on T-cell stimulatory capacity of cutaneous DCs.
DNFB-sensitized Thy1.2þ T cells were sorted from draining lymph nodes
5 days after DNFB application and incubated with or without CD11cþ DCs
prepared from draining lymph nodes 1 day after DNFB application with or
without FTY720 treatment. Cell proliferation was measured by 3H-thymidine
incorporation. d.p.m., decay per minute. When DCs without hapten
pretreatment were added in this assay, the enhancement of T-cell proliferation
was marginal (o2000 d.p.m.). Columns show the mean±SD from three
independent experiments.
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Figure 5. Numerical alternations of naive, central, and effector memory
T cells in the blood following FTY720 administration. FTY720 was
administered to B6 mice, and peripheral blood was periodically collected.
Lymphocytes were stained with mAbs to CD4 and CD44 and analyzed by
flow cytometry (a). The numbers of naive (b), central memory, (c) and effector
memory T cells (d) per milliliter of blood were determined. Columns show
the mean±SD from four mice per group. Student’s t-test was performed
between the indicated groups. *Po0.05. Data are from three independent
experiments.
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The expression of CCR7 and CD62L divides memory
T cells into two functionally distinct subsets (Sallusto et al.,
1999; Masopust et al., 2001; Reinhardt et al., 2001; Wherry
et al., 2003): those that express CD62L and CCR7 and
efficiently home to lymph nodes are termed central memory
cells and those that lack the expression of these lymph node
homing receptors and are preferentially located in non-
lymphoid tissues are termed effector memory cells. Both
T-cell subsets are present in the blood, lymph nodes,
and spleen. Some studies have also shown that effector
memory T cells acquire effector functions such as cytokine
production and cytotoxicity more rapidly than central
memory T cells do (Matloubian et al., 2004). Therefore, we
further enumerated CD4þ CD44 CD62Lþ -naive T cells,
CD4þ CD44þ CD62Lþ central memory T cells, and CD4þ
CD44þ CD62L effector memory T cells in the blood after
FTY720 administration. The number of naive T cells was
decreased markedly 1 and 3 days after FTY720 treatment and
returned to the baseline level on day 5 (Figure 5b). Similarly,
but less remarkably, the number of central memory T cells
significantly declined 1 day after FTY720 treatment and
almost returned to the baseline level on day 3 (Figure 5c). In
contrast, the number of effector memory T-cell subsets was
not substantially affected by FTY720 treatment throughout the
experimental period (Figure 5c). Similar results were obtained
with CD8þ T-cell subsets, and T cells isolated from mice
sensitized with DNFB 5 days prior yielded virtually the same
data (data not shown). These results suggest that the
chemotactic response of naive T cells to S1P was more
sensitive to FTY720 than that of memory T-cell subsets,
and that among memory T-cell subsets, effector memory
T cells were less susceptible to FTY720 than central memory
T cells.
We also evaluated the kinetics of the T-cell composition in
the regional lymph nodes after FTY720 treatment by
enumerating T-cell subsets 1, 3, and 5 days after FTY720
treatment in comparison with FTY720 non-treatment. FTY720
did not affect the number of CD4þ CD44 CD62Lþ -naive
T cells, CD4þ CD44þ CD62Lþ central memory T cells,
or CD4þ CD44þ CD62L effector memory T cells
(Figure 6a–c).
S1P responsiveness of T-cell subsets
FTY720 inhibits T-cell emigration through inhibition of
S1P–S1P1 signaling (Sawicka et al., 2003). Therefore, as
a readout of S1P1 function on each T-cell subset, we
compared the S1P chemotactic response between CD4þ
CD44 CD62Lþ -naive T cells, CD4þ CD44þ CD62Lþ
central memory T cells, and CD4þ CD44þ CD62L effector
memory T cells, which were isolated from draining lymph
nodes of mice to which DNFB had been applied 5 days
earlier. Chemotaxis assay using transwells showed that naive
T cells had a good chemotactic response to S1P at a peak of
100 nM (Figure 7a). Consistent with the previous finding that
FTY720 treatment of mice ablates S1P responsiveness in
lymphocytes, T cells from mice treated with FTY720 lost the
ability to respond to S1P (data not shown). In contrast, central
memory T cells had a weak chemotactic activity to S1P at a
peak around 1–100nM, whereas effector memory T cells did
not show any chemotactic response to S1P (Figure 7b and c).
These results revealed that S1P chemotactic response was
high in naive T-cell subsets, marginal in effector memory
T-cell subsets, and very low in central memory T-cell subsets.
S1P1 mRNA expression in T-cell subsets
To measure S1P1 abundance in each T-cell subset, regional
lymph node cells were prepared from B6 mice primed with
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Figure 6. Numerical alternations of naive, central, and effector memory
T cells in the lymph nodes following FTY720 administration. FTY720 was
administered to B6 mice, and skin-draining (inguinal and axillary) lymph
nodes were periodically collected. The numbers of naive (a), central memory
(b), and effector memory T cells (c) per mouse were determined. Columns
show the mean±SD from four or five mice per group. Student’s t-test was
performed between the indicated groups, but no statistically significant
difference (Po0.05) compared with the FTY720-nontreated group was
detected. Data are from two independent experiments.
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DNFB 5 days before, and CD4þ CD44 CD62Lþ -naive
T cells, CD4þ CD44þ CD62Lþ central memory, and CD4þ
CD44þ CD62L effector memory T cells were purified by a
cell sorter. We evaluated S1P1 mRNA levels by quantitative
PCR and found that memory T cells had one-fifth of the S1P1
transcript level of naive T cells. Among memory T-cell
subsets, effector memory T cells exhibited half the level of
transcript of central memory T cells (Figure 8).
DISCUSSION
The results from this study support several major conclusions.
First, CHS as a model of acquired skin immune response was
inhibited by treatment with FTY720 during the sensitization
but not the elicitation phase. Second, FTY720 did not
modulate cutaneous DC functions in relation to CHS. Third,
FTY720 decreased the number of circulating naive T cells
more markedly than that of memory T cells. Among memory
T cells, effector memory T cells were less susceptible to
FTY720 than central memory T cells. Accordingly, the
chemotactic response to S1P was high in the naive T-cell
subset, modest in the central memory T-cell subset, and
almost negligible in the effector memory T-cell subset.
Finally, S1P1 expression level was higher in naive T cells
than in memory T cells.
It has generally been thought that FTY720 causes
immunosuppression through enhancement of lymphocyte
sequestration into secondary lymphoid organs, thereby
preventing their Ag-activated T-cell egress to sites of
inflammation. However, it remains controversial whether
the effect of FTY720 is prophylactic or therapeutic. FTY720
was reported to have preventive value as observed in animal
skin allograft rejection and in the experimental autoimmune
encephalomyelitis model (Yanagawa et al., 1998; Luo et al.,
1999; Yanagawa et al., 1999). On the other hand, there have
been two reports on the possible therapeutic role of FTY720
as seen in autoimmune and immune responses provoked by
Ag-specific Th1 and Th2 (Sawicka et al., 2003; Graler and
Goetzl, 2004). FTY720 was shown to prevent or reduce
relapse of human multiple sclerosis (Dev et al., 2008) and
memory T-cell-mediated colitis (Fujii et al., 2006). Recently,
it was reported that FTY720 affected trafficking of lympho-
cytes to the epithelium (Kunisawa et al., 2007). An interesting
issue to be pursued in the future is whether FTY720 modu-
lates T-cell migration to the skin. In this study, we
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Figure 8. Quantitative PCR analysis of S1P1 mRNA from T-cell subset.
Lymph node cells from B6 mice 5 days after sensitization with DNFB were
sorted into CD4þ CD44 CD62Lþ naive, CD4þ CD44þ CD62Lþ central
memory, and CD4þ CD44þ CD62L effector memory T cells. The amounts
of S1P1 mRNA were expressed as relative amount of mRNA normalized to
b-actin, and S1P1 mRNA of naive T cells were set to 1. Data are from
three independent experiments.
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demonstrated that the major action phase of FTY720 on CHS
is the sensitization but not the elicitation limb, and therefore
FTY720 functions as a prophylactic but not therapeutic
modality in a mouse CHS model. Although the reason for
this discrepancy remains unknown, the differences might
be due to the animal models used, the type of immune or
autoimmune diseases, and the extent of central/effector
memory T cells involved.
It has been a matter of controversy whether FTY720
impairs the egress of memory T-cell subsets from the
secondary lymphoid organs. Some investigators sought to
evaluate the effect of FTY720 on circulating T-cell subsets,
but the number of memory T cells was too low to assess
precisely (Chiba et al., 1998). Another group of investigators
reported that activated T cells stimulated with anti-CD3 and
anti-CD28 antibody (Ab) lost their chemotactic activity to S1P
(Fujii et al., 2006). Here we demonstrated that circulating
memory T cells were resistant to FTY720 and that Ag-specific
memory T cells were transferable and capable of inducing
skin inflammation even in recipients treated with FTY720,
suggesting that FTY720 does not affect memory T-cell egress
from the secondary lymph nodes into the circulation.
Accordingly, memory T cells—especially effector memory
T cells—lost the chemotactic response to S1P, and circulating
memory T cells were detected in the blood, indicating the
possible existence of a mechanism other than S1P–S1P1
signaling underlying memory T-cell egress from the regional
lymph nodes.
Another controversial issue has been whether FTY720
affects lymphocytes in the regional lymph nodes. Although
FTY720 was suggested to deplete naive T cells in peripheral
lymphoid organs (Hofmann et al., 2006), we found that the
number of naive T cells in the regional lymph nodes after
sensitization with DNFB was not changed by FTY720 in our
experimental settings (data not shown). Interestingly, recent
data showed that increased S1P in inflamed peripheral tissues
induced T-cell retention and suppressed T-cell egress from
those tissues (Ledgerwood et al., 2008). How FTY720 affects
the homeostasis of lymphocytes in the skin under skin
inflammation such as CHS response is an issue to be pursued
in the future.
We speculate about the mechanisms underlying the
hyposensitization by FTY720 as follows: FTY720 administra-
tion during sensitization reduced the number of circulating
naive T cells by inhibiting their emigration to the peripheral
blood as demonstrated herein and by accelerating lympho-
cyte homing to lymph nodes and Peyer’s patches as reported
in another study (Idzko et al., 2002). We hypothesize that the
inhibitory effect of FTY720 on CHS stems from this dynamic
change of T-cell circulation. It has been thought that there
exist about 1 109 lymphocytes in one entire mouse, but
there are only 1107 lymphocytes in the draining lymph
nodes of the abdominal skin. Therefore, a great number of
naive T-cell clones may be supplied from the blood to the
lymph nodes, where they are converted to memory T cells.
Given that very few naive T cells are present in the
circulation after FTY720 administration, the frequency of
Ag-bearing DCs interacting with Ag-specific naive T-cell
clones might be reduced to 1/100 of those in FTY720-
nontreated mice. In fact, FTY720 treatment did not com-
pletely abrogate the CHS response (see Figure 1a), suggesting
that naive T cells remaining in the regional lymph nodes may
participate in the incomplete establishment of CHS response.
We assume that this reduction in the incidence of DC–T-cell
interaction may lead to impairment of the acquired skin
immune response.
One of the important factors in the initiation of acquired
skin immune response is the role of DCs. It is controversial
how DC functions are controlled by S1P and thus are
modified by FTY720. The responsiveness of DCs to S1P has
been variously reported, as S1P attracts human blood
monocyte-derived immature but not mature DCs (Czeloth
et al., 2005), murine mature but not immature DCs (Renkl
et al., 2004), or both immature and mature murine DCs
(Idzko et al., 2006). On the other hand, the local application
of FTY720 by inhalation suppressed murine allergic asthma
by inhibiting the migration of lung DCs to the mediastinal
lymph nodes (Idzko et al., 2006), and FTY720 inhibited FITC-
induced DC migration in a certain condition (Czeloth et al.,
2005). Recent studies have highlighted differences between
LCs and dermal DCs that migrate from skin to draining LNs
(Kissenpfennig and Malissen, 2006; Schroder et al., 2006;
Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al., 2007).
It would be valuable to know whether FTY720 has a
measurable effect on the migration of the individual subsets.
However, there was no effect of FTY720 on each subset in
migration activity. In addition, we could not detect the
functional modulation of DCs by FTY720 in our experimental
settings.
Our present study provides a previously unidentified
finding that FTY720 impairs naive T-cell circulation, thereby
markedly disrupting the acquired skin Th1 type immune
response. Consequently, FTY720 may have the potential to
prevent the onset of disease rather than to treat memory
T-cell-mediated acquired skin immune responses. Further
investigations on the mode of action of FTY720 may increase
its clinical usage and provide additional insights into the
means of effectively manipulating immune responses in vivo.
MATERIALS AND METHODS
Animals and reagent
Female C57BL/6 (B6) mice at 8 weeks of age were purchased from
Japan SLC (Hamamatsu, Japan). Mice were maintained on a 12-hour
light/dark cycle under specific pathogen-free conditions. Protocols
were approved by the Institutional Animal Care and Use Committee
of the University of Occupational and Environmental Health.
For treatment with FTY720 (Novartis Pharmaceuticals, Basel,
Switzerland), B6 mice were injected intraperitoneally with
1.0mg kg1 of FTY720 or with an equivalent volume of normal
saline at the indicated time points.
Cell preparation and cultures
RPMI-1640 (Sigma, St Louis, MO) containing 10% heat-inactivated
fetal calf serum (Invitrogen, Carlsbad, CA), 5 105 M 2-mercap-
toethanol, 2mM L-glutamine, 25mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; Cellgro, Herndon, VA), 1mM
www.jidonline.org 2839
D Nakashima et al.
FTY720 and Contact Hypersensitivity Response
nonessential amino acids, 1mM sodium pyruvate, 100Uml1 peni-
cillin, and 100mgml1 streptomycin was used as a culture medium
unless otherwise stated. Blood leukocytes were isolated by cardiac
puncture and red blood cell lysis buffer (Kabashima et al., 2006).
Flow cytometry and histology
Cell suspensions were prepared from lymph nodes by mechanical
disruption on 70 mm nylon cell strainers (BD Falcon, San Jose, CA).
For flow cytometry, cells were plated at a density of 1 106 cells per
well in 96-well U-bottomed plates (BD Falcon). They were stained
for 20minutes on ice with Abs in 25 ml of phosphate-buffered saline
containing 2% fetal calf serum, 1mM EDTA, and 0.1% NaN3, and
were then washed twice with 200ml of this buffer after each step
(Kabashima et al., 2007). Data were collected on a FACSCanto (BD
Biosciences, San Diego, CA) and analyzed with FlowJo software
(TreeStar, San Carlos, CA). Abs used were FITC-conjugated anti-
CD62L Ab, PE-conjugated anti-CD44 and CD86 Abs, PE-Cy5-
conjugated anti-MHC class II Ab, PE-Cy7-conjugated CD4 Ab, and
allophycocyanin-conjugated anti-CD11c Ab (all from BD Bios-
ciences). For detection of Langerin, anti-Langerin Ab (eBioscience,
San Diego, CA) was used after fixation and permeabilization by the
cytofix/cytoperm kit (BD Bioscience).
For histological analysis, the ears of B6 mice 24 hours after
challenge with hapten were excised and fixed in 10% formaldehyde.
Sections of 5 mm thickness were prepared and stained with
hematoxylin and eosin.
Cell sorting and quantitative PCR
Naive, central memory, and effector memory T cells from lymph node
cells of B6 mice sensitized with DNFB 5 days earlier were isolated
with a cell sorter (EPICS Elite, Becton Dickinson, Franklin Lakes, NJ).
The purity of the sorted cells was typically490%. RNA was prepared
from sorted cells with RNeasy (Qiagen, Valencia, CA), and cDNA was
used for quantitative PCR. Murine S1P1 (Assay ID: Mm00514644_m1)
expression was quantified using TaqMan Gene Expression Assay
(Applied Biosystems) in the ABI PRISM 7000 sequence detection
system (Applied Biosystems, Foster City, CA). As an endogenous
reference for these PCR quantification studies, b-actin gene expression
was measured using the TaqMan rodent b-actin control reagents
(Applied Biosystems). The relative expression was calculated using the
2DDCT method (Livak and Schmittgen, 2001). The expression of the
target gene normalized to an endogenous reference and relative to
calibrator was given by the formula 2DDCT . Gene expression in
untreated mice was used as a calibrator expression to calculate DDCT.
Chemotaxis assay and FITC-induced cutaneous DC migration
Regional lymph node cells 5 days after DNFB application to the
abdomen were tested for transmigration across uncoated 5-mm
transwell filters (Corning Costar Corp., Corning, NY) to S1P (Sigma-
Aldrich, St Louis, MO) or medium in the lower chamber for 3hours,
and the migrated cells were enumerated by flow cytometry
(Kabashima et al., 2006). The medium used in this assay was RPMI-
1640 with 0.5% fatty acid-free BSA (Calbiochem, San Diego, CA).
For FITC-induced cutaneous DC migration, the shaved abdomens
of mice were painted with 200 ml of 2% FITC (Sigma) dissolved in 1:1
(vol/vol) (Sigma), and the number of migrated cutaneous DCs into
draining inguinal and axillary lymph nodes was determined by flow
cytometry (Kabashima et al., 2003b).
DNFB-induced CHS model and adoptive transfer
For the CHS model, B6 mice were immunized by application of
25 ml of 0.5% DNFB in 4:1 (vol/vol) acetone/olive oil to their shaved
abdomens on day 0. They were challenged on the right ear on days
5, 10, or 15 with 20 ml of 0.3% (vol/vol) DNFB (Kabashima et al.,
2003a). Ear thickness was measured before and 24 hours after
challenge, and the change in ear thickness was calculated as
follows: (ear thickness 24 hours after challenge)–(ear thickness before
challenge).
For adoptive transfer, regional axillary and inguinal lymph node
cells were prepared from B6 mice sensitized with 25 ml of 0.5%
DNFB on the abdomen 5 days earlier. Mice were pre-administered
with or without FTY720 12 hours before being sensitized. Thy1.2þ
T cells were purified with beads conjugated with anti-Thy1.2 Ab
(Miltenyi Biotec, Auburn, CA) using auto MACS (Miltenyi Biotec)
according to the manufacturer’s protocol. Sorted T cells (5 106,
purity 495%) were injected intravenously into naive B6 mice
treated with FTY720 or control normal saline 12 hours earlier. The
ears of the mice were challenged with 20 ml of 0.3% DNFB 1 hours
later, and ear thickness was measured before and 24 hours after
challenge.
For the cell proliferation assay, Thy1.2þ T cells were purified
from axillary and inguinal lymph nodes 5 days after 25 ml of 0.5%
DNFB application to the abdomen. Similarly, CD11cþ DCs were
sorted from regional lymph nodes 1 day after DNFB application to
the abdomen of mice treated with FTY720 or control normal saline
12 hours earlier. The sorted T cells (5 105, purity 495%) by auto-
MACS were incubated for 72 hours with or without purified Ag-
loaded DCs (5 104, purity470%), pulsed with 1 mCi 3H-thymidine
for the last 24 hours of culture, and subjected to a liquid scintillation
counter.
Statistical analysis
Data were analyzed using an unpaired two-tailed t-test. Po0.05 was
considered to be significant.
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